Hemogenyx Pharmaceuticals PLC

LSE:HEMO

HemoGenyx Pharmaceuticals Plc operates as a biopharmaceutical company, which engages in the development of novel therapies to transform bone marrow and blood stem cell transplantation. The firm is engaged in the discovery, development, and commercialization of a suite of products to address the problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, with viral infections, and with bone marrow, or hematopoietic stem cell, transplants. The Company’s product candidates include CDX antibody, CAR-T cell therapy, Hu-PHEC stem cell therapy, Humanised mice, and CBR platform. Its CDX antibody product, is a bispecific antibody targeting a form of relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia (ALL), and myelodysplastic syndrome. CAR-T cell therapy is a chimeric antigen receptor T-cells that are engineered for use in immunotherapy. The Company’s human postnatal hemogenic endothelial cells (Hu-PHECs) are a type of cell therapy that generate cancer-free hematopoietic stem cells for use in transplants to treat blood disorders.